Previous 10 | Next 10 |
– CFT7455 Demonstrated High Binding Affinity to Cereblon and Target Selectivity in Non-Hodgkin’s Lymphoma Cell Models, Producing Rapid and Deep Degradation of IKZF1/3 Proteins – – CFT7455 Resulted in Improved Efficacy and Potency in Tumor Xenograft Mo...
C4 Therapeutics (CCCC) has priced its public offering of 4.25M common shares at $37.00/share, for expected gross proceeds of ~$157M. Underwriters' over-allotment is an additional 637.5K shares.Closing date is June 21. J.P. Morgan, Jefferies, Evercore ISI, BMO Capital Markets and UBS Investmen...
WATERTOWN, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced the pricing of...
C4 Therapeutics (CCCC) announces that it has launched a proposed public offering of 4.25M shares.In addition, the company expects to grant the underwriters a 30-day option to purchase up to 637.5K additional shares.Intends to use the net proceeds of the offering to fund the company’s r...
WATERTOWN, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that it has la...
C4 Therapeutics (CCCC) announces that the first patient has been dosed in the company’s trial of CFT7455 for the treatment of multiple myeloma and non-Hodgkin’s lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma.The company said that it expects to share dat...
WATERTOWN, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the first...
C4 Therapeutics ([[CCCC]] +4.8%) has approached its highest level since mid-March after the company announced pre-clinical data for CFT8919 a potential therapy against non-small cell lung cancer ((NSCLC)).The mutant-selective degrader of epidermal growth factor receptor ((EGFR)) has...
– CFT8919 Induces Tumor Regression in Pre-clinical Models Resistant to First- and Third-generation EGFR Inhibitors – – CFT8919 Demonstrates Intracranial Activity Pre-clinically, Indicating the Potential to be Effective Against CNS Metastases – ...
C4 Therapeutics (CCCC) announces that it has decided to advance CFT8919, a novel degrader of epidermal growth factor receptor ((EGFR)) in non-small cell lung cancer ((NSCLC)), into investigational new drug ((IND))-enabling studies.The company also said that it anticipates filing an IND for th...
News, Short Squeeze, Breakout and More Instantly...
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing...
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the UBS Targeted Prote...
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform t...